NEW YORK (GenomeWeb News) – Lentigen has licensed an HIV-related lentiviral vector technology patent held by the University of Cambridge, the company said today.
Baltimore-based Lentigen signed an exclusive agreement with Cambridge Enterprise, the technology licensing arm of the University of Cambridge, for technology that was developed by Andrew Lever.
"The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies," said Boro Dropulic, who is Lentigen’s founder, president, and chief scientific officer.
The licensing deal follows the acquisition of Cell Genesys’ lentiviral patent portfolio late last year by GBP Capital, who is Lentigen’s majority shareholder.
Financial terms of the agreement were not released.